Douglas Tsao, an analyst from H.C. Wainwright, reiterated the Buy rating on Hansa Biopharma AB. The associated price target remains the same with SEK143.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Douglas Tsao has given his Buy rating due to a combination of factors surrounding Hansa Biopharma AB’s recent clinical trial success. The Phase 3 ConflideS trial demonstrated that imlifidase, the company’s lead product, achieved both primary and secondary endpoints with significant clinical outcomes. This trial involved highly sensitized kidney transplant patients and showed that those treated with imlifidase had notably better kidney function after 12 months compared to the control group.
These results are crucial as they align with established clinical guidelines and academic findings, suggesting a substantial improvement in patient outcomes. The positive data from this trial not only strengthens the case for FDA approval but also supports the potential for widespread adoption of imlifidase in the U.S. market. The achievement of dialysis independence as a secondary endpoint further underscores the therapeutic value of imlifidase, reinforcing the Buy rating as the company prepares for a Biologics License Application submission by the end of 2025.